Search
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … [A247035] This is possible thanks to the tetrazole moiety in oteseconazole that increases target selectivity.
MGN-4893
go.drugbank.com/drugs/DB17338ExperimentalMGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]
Synonyms: MGN 4893Haemagglutinin-strain B (Victoria-like)
go.drugbank.com/drugs/DB15473ApprovedMixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeAG-858
go.drugbank.com/drugs/DB05502InvestigationalTumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. … AG-858 (autologous heat-shock protein 70 peptide vaccine) is a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes.
Orris
go.drugbank.com/drugs/DB10413ApprovedOrris allergenic extract is used in allergenic testing.
Mixtures: Cleansing Foaming Gel Acne Pro SkinMK-4541
go.drugbank.com/drugs/DB17016ExperimentalMK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.
Synonyms: 2,2,2-trifluoroethyl N-[(1S,3aS,3bS,5aR,9aR,9bS,11aS)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinolin-1-yl]carbamateBrasofensine
go.drugbank.com/drugs/DB04857ExperimentalIn November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]
Categories: Complex MixturesRemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … In clinical studies, patients treated with remestemcel-L demonstrated an improvement in their aGvHD and improved survival rates at subsequent days following intravenous infusion [L11022].
Categories: Complex MixturesZedenoleucel
go.drugbank.com/drugs/DB18639InvestigationalMT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.